Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples